ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ARWR vs PRAX // DIVIDEND YIELD & FCF PAYOUT SAFETY

Arrowhead Pharmaceuticals Inc. (NASDAQ) VS. Praxis Precision Medicines Inc. (NASDAQ) • 15-METRIC TALLY: ARWR 7 — PRAX 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARWR VS. PRAX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ARWR PRAX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 11.10% -35.00% +46.10 ARWR /roic <GO>
EV/EBITDA & P/E Valuation 73.8x — — TIE /valuation <GO>
Free Cash Flow Yield 1.84% -3.09% +4.93 ARWR /fcf-yield <GO>
Operating Margin 11.90% — — TIE /operating-margins <GO>
Net Profit Margin -0.20% — — TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% 8.80% +171.20 ARWR /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 6.60 26.00 -19.40 PRAX /balance-sheet <GO>
Piotroski F-Score Quality 8/9 5/9 +3.00 ARWR /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.3 56.3 -13.00 PRAX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.96 0.91 +0.05 ARWR /macro-sensitivity <GO>
Forward P/E Multiple 18.0x 33.0x -15.00 ARWR /forward-pe <GO>
Enterprise Scale & Market Cap $8.54B $8.06B $486.2M ARWR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ARWR REV PRAX REV ARWR GROSS % PRAX GROSS % ARWR FCF PRAX FCF
FY 2025 $829.4M $0 — — $156.9M -$249.1M
FY 2024 $3.6M $8.6M — — -$604.3M -$131.8M
FY 2023 $240.7M $2.4M — — -$164.7M -$111.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARWR // BETA 0.96
PRAX // BETA 0.91